In order to accelerate the construction and support of the Lecheng Pioneer Zone platform, summarize and share the experience of real world research projects, on July 30th, the signing ceremony for the China Eye Valley strategic cooperation of the Boao Lecheng Medical Industry Transformation Platform and the Oukangwei Shiyou Shiying Real World Research Project Sharing Meeting were held in the Lecheng Pioneer Zone of Boao.

Launch of China Eye Valley Strategic Cooperation on Boao Lecheng Medical Industry Transformation Platform

Celebrating the approval of the new drug Youshiying for the treatment of chronic non infectious uveitis

Jia Ning, Secretary of the Party Committee and Director of the Management Bureau of Hainan Boao Lecheng International Medical Tourism Pilot Zone, Qu Jia, General Dean of Wenzhou Medical University Ophthalmology Hospital Group, Chairman of China Eye Valley, and Executive Dean of Hainan Real World Data Research Institute, Li Zhiping, former First Class Inspector of Hainan Market Supervision Administration, Li Yunda, Deputy Director of Hainan Drug Administration, and Executive Dean of Hainan Real World Data Research Institute Professor Chen Pingyan from Southern Medical University, Director of the China Evidence Based Medicine Center at West China Hospital of Sichuan University, and Director of the Hainan Real World Data Research and Evaluation Key Laboratory of the State Food and Drug Administration, Sun Xin, Executive Vice President of Boao Super Hospital, Liu Tongting, Vice President of Wenzhou Medical University Affiliated Ophthalmology Hospital and Director of the Ophthalmology Center at Boao Super Hospital, Chen Wei, Vice President of Wenzhou Medical University Affiliated Ophthalmology Hospital, and Director of the Staphylococcus Disease Department at Wenzhou Medical University Affiliated Ophthalmology Hospital, Wang Yuqin, Xu Liangde, Executive Director of Wenzhou Eye Vision International Innovation Center (China Eye Valley), Liu Mimi, Deputy Director of Hainan (Boao) International Eye Vision Ophthalmology Hospital, Chen Donghong, Chief Medical Officer of Oukang Weishi Biopharmaceutical Co., Ltd., and Hu Zhaopeng, Chief Development Officer, and other leading experts attended the event online and offline.

China's Eye Valley Settles in Boao Music City

Building an innovative and transformed industrial cluster for eye and brain health

The first public platform for medical technology innovation in the leading area of Boao Lecheng, the Boao Lecheng Medical Industry Transformation Platform, was officially launched on July 29th, with many well-known scientific research institutions and leading domestic and foreign enterprises rushing to layout. Among them, Professor Qu Jia, Director of the Department of Ophthalmology and Optometry at Wenzhou Medical University, founded the "Tower Point Heavy Weapon" - China Eye Valley, which will leverage its global influence, integrate and utilize international resources, and cooperate with Lecheng Management Bureau to jointly build the Lecheng Medical Industry Transformation Platform China Eye Valley project.

At the event site, the Boao Lecheng Pilot Zone Management Bureau signed a strategic cooperation agreement with Wenzhou Eye Vision International Innovation Center, and officially launched the Boao Lecheng Medical Industry Transformation Platform China Eye Valley project.

Jia Ning, Secretary of the Party Committee and Director of the Boao Lecheng Pilot Zone Management Bureau, congratulated the launch of the signing of the Boao Lecheng Medical Industry Transformation Platform China Eye Valley Strategic Cooperation and the approval of the launch of the Youshiying Real World Research Project. He pointed out that in recent years, the business environment of Lecheng Pilot Zone has been continuously optimized, and the "strong magnetic field" effect has been continuously released, attracting many industry-leading market entities to invest, providing strong impetus and source vitality for Lecheng Pilot Zone to promote the transformation and landing of more medical technology innovation projects and achieve industrial clustering. I hope that various market entities can continue to support and actively participate in the construction of the Lecheng Medical Industry Transformation Platform and the real world research work of Lecheng. The Lecheng Management Bureau will continue to work with relevant departments to provide better and more refined services, promoting the transformation and implementation of more medical technology innovation achievements in the Lecheng Pilot Zone.

Qu Jia, General Dean of Wenzhou Medical University Eye and Optometry Hospital Group and Chairman of China Eye Valley, stated that the Boao Lecheng Medical Industry Transformation Platform China Eye Valley Project will benchmark overseas high-end technologies, industries, and talents, introduce ophthalmic and pharmaceutical enterprises and innovation teams to settle in, incubate technology transformation projects, and jointly build joint research institutes with leading enterprises in the field of ophthalmology to promote eye diseases, optometry We strive to develop and transform technology products such as eye and brain health, as well as cultivate high-tech industries, in order to create a globally influential China Eye Valley Eye and Brain Health Innovation Cluster in Boao Lecheng.

Government set up platform, experts contribute wisdom, and enterprises participateLecheng Clinical Real World Data Application Pilot Achieved fruitful results

In June of this year, Youshiying (Flupron Intravitreous Implant) was approved for import registration and listing by the National Food and Drug Administration. This is the first drug in China to be approved for import registration based on overseas clinical trial data and domestic patient clinical real-world data, marking another milestone in the pilot work of Lecheng clinical real-world data application.Yushiying (Flupron intravitreal implant) has the characteristics of low dose intraocular administration and continuous drug release for up to 36 months. It is the first and only new drug approved by the FDA to release Flupron for up to 36 months for the treatment of chronic non infectious uveitis involving the posterior segment of the eye.Relying on the preferential policy of "privileged access, first trial" granted by the state to the Boao Lecheng Pilot Zone, Youshiying completed its first domestic application at Boao Super Hospital in August 2019, providing a powerful treatment method for chronic non infectious uveitis in China.

Li Yunda, Deputy Director of the Hainan Provincial Food and Drug Administration, stated that the approval for the domestic market of fluoxetine intravitreal implants is a breakthrough achievement achieved in the real world data application pilot work of Boao Lecheng under the correct leadership of the National Food and Drug Administration and the careful guidance of the National Drug Approval Center. This has accelerated the accessibility of global innovative products for clinical use in China, promoted the reform of the drug review and approval system It is of great significance to better meet the needs of the people to use high-quality drugs. The Hainan Provincial Drug Administration will continue to improve the communication and exchange mechanism with the National Drug Examination Center and Lecheng Administration, jointly explore and promote the pilot work of clinical real world data application, and build Lecheng into a highland for real world research.

Liu Tongting, Executive Vice President of Boao Super Hospital, introduced that in order to help accelerate the evaluation of Shi Ying's real world research project, the hospital actively cooperates with the Hainan Provincial Drug Administration, the Provincial Health Commission, Haikou Customs, Lecheng Management Bureau and other departments to coordinate and coordinate various aspects of work. The successful completion of this project is another milestone achieved by Boao Super Hospital in actively responding to the call of the party and government to introduce imported licensed medical equipment.

Youshiying Real World Research Clinical PI is Professor Qu Jia, General Dean of Wenzhou Medical University Ophthalmology Hospital Group and Chairman of China Eye Valley, and Professor Chen Wei, Vice President of Wenzhou Medical University Affiliated Ophthalmology Hospital. The head of real world research design and statistical analysis methods is Professor Sun Xin, Director of the Hainan Real World Data Research and Evaluation Key Laboratory of the National Drug Administration.

This event specially invited multiple experts and scholars who participated in the Youshiying real world research project and deeply participated in the real world research work of Lecheng to summarize and share the experience of project practice, providing valuable reference and suggestions for further exploration of real world research.

Chen Pingyan, Executive Dean of Hainan Real World Data Research Institute and Professor of Southern Medical University, shares the "Real World Research Guidelines to Assist Clinical Drug Development"

Professor Chen Wei, Vice President of Wenzhou Medical University Affiliated Ophthalmology Hospital and Director of the Ophthalmology Center of Boao Super Hospital, shared the "Real World Research Supporting Global Ophthalmology Innovation and Device Transformation - Boao Lecheng Practice"

Dr. Yao Minghong from Sun Xin, Director of the Hainan Real World Data Research and Evaluation Key Laboratory of the State Food and Drug Administration, shares "Design and Analysis of Youshiying Real World Research"

Wang Yuqin, Director of the Staphylococcus Disease Department at the Eye and Optometry Hospital Affiliated to Wenzhou Medical University, published the "Experience Sharing of Flupronil Sustained Release Agents in Upgraded Treatment of Uveitis"

Liu Mimi, Deputy Director of the Ophthalmology and Ophthalmology Center of Boao Super Hospital, shares his thoughts on the "New Practice of Drug Clinical Research - The Real World Research Project of Youshiying"

On the same day, another innovative product of Oukangweishi, OT-703 (0.19mg fluorelaxed intravitreal implant) for the treatment of diabetes macular edema, was officially launched as a real world research project.